Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00656643 |
Recruitment Status
:
Completed
First Posted
: April 11, 2008
Last Update Posted
: January 10, 2013
|
Sponsor:
Santen Inc.
Collaborator:
MacuSight, Inc.
Information provided by (Responsible Party):
Santen Inc.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review
by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | November 2009 |
Actual Study Completion Date : | May 2012 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 | May 2, 2017 | May 31, 2017 |